Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

(Reuters) -Swiss drugmaker Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter. Reuters could not immediately confirm the report. (Reporting by Dheeraj Kumar in Bengaluru; Editing by Aidan Lewis)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)